Assessment of the targeted effect of Sijunzi decoction on the colorectal cancer microenvironment via the ESTIMATE algorithm

Jiaxin Du, Quyuan Tao, Ying Liu, Zhanming Huang, He Jin, Wenjia Lin, Xinying Huang, Jingyan Zeng, Yongchang Zhao, Lingyu Liu, Qian Xu, Xue Han, Lixia Chen, Xin-lin Chen, Yi Wen

School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China, Shenzhen Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China

Abstract

Objective

Sijunzi decoction (SJZD) was used to treat patients with colorectal cancer (CRC) as an adjuvant method. The aim of the study was to investigate the therapeutic targets and pathways of SJZD towards the tumor microenvironment of CRC via network pharmacology and the ESTIMATE algorithm.

Methods

The ESTIMATE algorithm was used to calculate immune and stromal scores to predict the level of infiltrating immune and stromal cells. The active targets of SJZD were searched in the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and UniProt database. The core targets were obtained by matching the differentially expressed genes in CRC tissues and the targets of SJZD. Then, GO, KEGG and validation in TCGA were carried out.

Results

According to the ESTIMATE algorithm and survival analysis, the median survival time of the low stromal score group was significantly higher than that of the high stromal score group (\(P = 0.018\)), while the patients showed no significant difference of OS between different immune groups (\(P = 0.19\)). A total of 929 genes were upregulated and 115 genes were downregulated between the stromal score groups (\(|\log\text{FC}| > 2, \text{adjusted } P < 0.05\)); 357 genes were upregulated and 472 genes were downregulated between the immune score groups. The component-target network included 139 active components and 52 related targets. The core targets were \(HSPB1\), \(SPP1\), \(IGFBP3\), and \(TGFB1\), which were significantly...
associated with poor prognosis in TCGA validation. GO terms included the response to hypoxia, the extracellular space, protein binding and the TNF signaling pathway. Immunoreaction was the main enriched pathway identified by KEGG analysis.

Conclusion

The core genes (HSPB1, SPP1, IGFBP3 and TGFBI) affected CRC development and prognosis by regulating hypoxia, protein binding and epithelial-mesenchymal transition in the extracellular matrix.

Introduction

Cancer development and progression are complex processes caused by the accumulation of genetic modifications in cancer cells and influenced by the surrounding microenvironment. Cancer cells recruit vascular and stromal components (including immune cells, fibroblasts, cytokines, and the extracellular matrix that surrounds them) to the tumor microenvironment (TME), and the activated TME in turn modifies the malignant behaviors of cancer cells [1]. Numerous studies have indicated that infiltrating immune cells in the TME fail to execute antitumor functions but interact intimately with tumor cells to promote oncogenesis and progression. Both innate and adaptive immune cells are involved in this cross-talk [2].

Colorectal cancer (CRC) is a kind of digestive tract tumor, mostly affecting the colon, that is influenced by multiple factors, such as genetics, environment, and diet. With changes in dietary structure and the deterioration of the natural environment, the incidence and mortality of CRC continue to rise [3–5]. In 2018, there were 18.1 million new cancer cases and 9.6 million cancer-related deaths worldwide. China has the highest cancer incidence and mortality rates in the world, and CRC ranks fourth in the incidence and second in the mortality rate among malignant tumors in China [6]. At present, surgical resection is still the only treatment that can completely cure CRC. However, since the initial symptoms of patients with CRC are not obvious, most patients are diagnosed at the late stage when surgery is not an option [7]. Moreover, up to 15% of patients develop major complications, and postoperative recurrence and metastasis are common [8]. Although the chemotherapy combination of 5-fluorouracil with oxaliplatin has been shown to reduce the rates of metastasis and recurrence in advanced CRC [9, 10], long-term chemoradiotherapy, like many chemotherapy-related strategies, has adverse effects, such as organ damage, myelosuppression, cumulative neuropathy, severe reduction in the quality of life of patients and drug resistance [11, 12].

Traditional Chinese medicine (TCM) plays an indispensable role in the integrative treatment of advanced CRC and has been widely used in China and other parts of Asia. It has been widely reported that TCM could prolong the survival time and improve the quality of life of patients with CRC by preventing tumorigenesis, suppressing tumor growth, and reducing metastasis and recurrence [13–16]. Moreover, as an adjunct therapy, TCM could increase the sensitivity and alleviate the side effects of chemotherapy or radiotherapy, improve immunity, lessen the damage induced by conventional treatments, and ameliorate bone marrow suppression [11, 17–20]. Sijunzi decoction (SJZD), which consists of Panax Ginseng C. A. Mey, Atractylodes Macrocephala Koidz, Poria cocos Wolf and licorice, is a classical prescription for curing temper deficiency syndrome in TCM. It has long been widely used in the clinic to treat CRC since it combats vomiting, diarrhea and nausea to restore homeostasis in the digestive tract [21–25]. Emerging evidence has shown that SJZD is beneficial for advanced CRC.
treatment, as it improves the quality of life of patients with Qi deficiency syndrome [26]. However, previous studies mainly focused on the differentially expressed genes (DEGs) between tumor tissues and nontumor tissues, but these studies were often insufficient and limited because they ignored the influence of TCM on the TME. Here, we predicted the levels of infiltrating stromal and immune cells by algorithmically calculating the stromal and immune score. The therapeutic targets of SJZD and the DEGs between different infiltration levels were intersected, and the core genes affected the TME of CRC were found. The result will provide the TME of CRC with a novel auxiliary therapeutic perspective.

Materials and methods

Data mining and processing of the CRC expression profile chip

The Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) database was generated and maintained through the National Center for Biotechnology Information (NCBI) Gene Expression database. The GEO includes high-throughput gene expression data submitted by research institutions around the world [27]. The datasets were considered to be appropriate for further analysis according to two criteria: (1) studies with CRC tissue samples and (2) studies with clinical prognostic data available for the samples. Based on these criteria, GSE31595 [28] and GSE17536 [29] were evaluated.

Potential variables and heterogeneity are commonly considered to be major sources of variability and bias in high-throughput experiments [30]. The obtained sample data were prone to error due to the small sample size and differences in sample handling and study design. Therefore, all samples from both datasets were integrated to significantly increase the sample size. Then, the scale function was used in R 4.0.2 software to normalize and standardize the samples.

Evaluation of the infiltration degree of stromal cells and immune cells based on the Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm

The ESTIMATE algorithm [31], which utilizes the unique properties of the transcriptional profiles of cancer samples to infer tumor cellularity and different degrees of infiltration of tumor and normal cells, was applied. To identify specific signatures related to the infiltration of stromal and immune cells, immune and stromal scores were calculated with the ESTIMATE algorithm, and these scores reflected the predicted level of infiltrating stromal and immune cells. In this study, the ESTIMATE package (https://CRAN.R-project.org/package=EstimateGroupNetwork) in R 4.0.2 was used to perform ESTIMATE scoring of the CRC samples. Besides, in order to compare the variation trends of immune and stromal score at different pathological stages, box plot was used to visualized the distribution characteristics of immune and stromal score at different American Joint Committee on Cancer (AJCC) stages.

Prognostic analysis of the ESTIMATE score

Based on the results of the ESTIMATE score (stromal score or immune score), the 214 samples were divided into two groups (high: ESTIMATE score ≥ median, and low: ESTIMATE score < median). To determine the validity of the ESTIMATE score, a prognosis analysis was utilized to analyze the relationship between the ESTIMATE score and the survival time of the patients with CRC, and survival curves were evaluated by Kaplan–Meier method. In the survival analysis, the clinical data of all patients were obtained from the previously downloaded data sets. Overall survival (OS) was defined as the time from the beginning of random
assignment to death (for patients still alive at the end of the study, the time of death was the end of follow-up).

**Gene set enrichment analysis**

To explore the significant biological pathway of different infiltration levels in the TME of CRC, gene set enrichment analysis (GSEA, http://software.broadinstitute.org/gsea/index.jsp) was performed in the immune and stromal group respectively. The expression matrix and grouping information (stromal high vs stromal low, immune high vs immune low) of 214 samples were used as input data. GSEA v4.1.0 software was used to evaluate the enrichment of biological pathway with “weighted” enrichment statistics. Enriched gene sets with false discovery rate (FDR) < 0.25, |normalized enrichment score (NES)| > 1, and nominal \( P < 0.05 \) were regarded as being statistically significant [32].

**Collection of active ingredients**

The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, http://tcmspw.com/tcmsp.php/) [33] was used to retrieve active compounds of SJZD based on absorption, distribution, metabolism, and excretion (ADME) [34]. This is a unique pharmacology platform devised for TCM to capture the disease-herb-target relationship.

As oral administration was the chief route of drug delivery of TCM, oral bioavailability (OB) was set as the major parameter in active constituent retrieval [35]. In this study, \( \text{OB} \geq 30\% \) and drug likeness (DL) \( \geq 0.18 \) were used as the standards to screen the effective active compound of SJZD [36].

**Drug target screening and core target gene acquisition of SJZD**

The effective active ingredients acquired from TCMSP in the previous step were further searched to obtain the corresponding target proteins. The standardized genes were retrieved through the UniProt database (https://www.Uniprot.org/) [37]. The active genes of Panax Ginseng C. A. Mey, Atractylodes Macrocephala Koidz, Poria Cocos Wolf and licorice were sorted out and introduced into Cytoscape V3.7.2 to establish the “compound-target” network diagram to visualize the overall situation of drug compounds and targets. The network topology analysis plug-in CytoNCA [38] in Cytoscape V3.7.2 was used to obtain the core compound and target gene of SJZD with a degree of freedom > 34 (twice the median). "Degree" reflects the number of links with each node in the network and the interaction relationship between nodes.

**Screening of core genes related to SJZD in CRC**

The stromal scores and immune scores of the samples were used as the grouping parameters for differential expression analysis. Stromal scores were classified into two groups: high stromal score group (HSS) and low stromal score group (LSS). Similarly, high immune score group (HIS) and low immune score group (LIS) were obtained. The DEGs of stromal groups or immune groups based on the TME were obtained using differential expression analysis (|Log2FC| > 2, adjusted \( P \leq 0.05 \)) according to the score groups (HSS vs LSS, HIS vs LIS) in the R package limma [39]. The therapeutic targets of SJZD for CRC obtained previously were intersected with these DEGs to obtain the core target genes of SJZD in CRC.

**Analysis of core target genes related to SJZD in CRC**

To explore the specific pathways and biological processes of the core target genes involved, gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway analysis were performed based on the clusterProfiler package [40]. Protein-protein interaction (PPI) were analyzed and constructed using the Search Tool for the Retrieval of Interacting Genes (STRING) database (https://string-db.org/cgi/input.pl) [41], which could retrieve further protein interactions of the core targets. The PPI network was visualized in Cytoscape V3.7.2. Topological analysis was carried out, and the degree value was used as a reference to determine the important core targets. To investigate the effect of these core target genes on the prognosis of CRC patients, a survival analysis was performed using the clinical data from GEO database (GSE31595 and GSE17536). In addition, considering the limited number of patient samples, we performed further survival analysis validation by using 530 colon adenocarcinoma (COAD) samples from the TCGA database.

Survival curves were drawn to screen core target genes with prognostic value ($P \leq 0.05$). The core target genes with prognostic value were called microenvironment-related prognostic genes.

**Results**

**Immune scores and stromal scores were associated with CRC stage**

First, the gene expression profiles and clinical characteristics of all 214 patients pathologically diagnosed with CRC were obtained from the GEO database. Among them, 103 patients were female (48.1%), and 111 patients were male (51.9%). The pathological classification of AJCC stage revealed 24 (11.2%) cases of stage I disease, 77 (36.0%) cases of stage II disease, 74 (34.6%) cases of stage III disease and 39 (18.2%) cases of stage IV disease.

According to the ESTIMATE algorithm, the ranges of stromal scores and immune scores were $-323.92$ to $5403.97$ and $-859.48$ to $6701.10$, respectively. According to the overall trend of the box plot, the stromal and immune score generally increased with the progression of AJCC stage (Fig 1A and 1B). Just in terms of the median value, the median of stage IV is lower than that of stage III, but still higher than that of stage II and stage I (Fig 1A). Similarly, the rank order of immune score for CRC stages was stage III > stage IV > stage II > stage I (Fig 1B), indicating that immune scores and stromal scores based on the ESTIMATE algorithm were positively correlated with the pathological diagnosis and clinical stage to a certain extent.

To assess the potential relationships between overall survival (OS) and immune scores and stromal scores, all the patients were divided into high score groups (≥ median ESTIMATE score) and low score groups (< median ESTIMATE score). Kaplan-Meier survival curves indicated that the median survival time of the low stromal score group was significantly higher than that of the high stromal score group (Fig 1D, $P = 0.018$), while the patients showed no significant difference of OS between different immune groups (Fig 1C, $P = 0.19$).

**Results of gene set enrichment analysis (GSEA)**

In the C5 enrichment analysis results, 658 gene sets were significantly enriched in the high score group; there were 10 enriched gene sets in the low score group. According to the immunization score-based grouping, 678 and 1 gene sets were significantly enriched for the high group and low group, respectively (S1 Appendix).

The results of C5 enrichment analysis in the high stromal score group showed that the infiltration of stromal cells in the TME of CRC might be related to the following biological functions: cytokine mediated signaling pathway, G protein coupled receptor signaling pathway coupled to cyclic nucleotide second messenger, B cell activation, side of membrane, and adaptive immune response (Fig 2B). According to the GSEA results, cytokine mediated signaling pathway was the most enriched biological function in high stromal score group (Fig 2A).
S1 Appendix), which could modulate the ability of cancer cell to grow, proliferate, invade, and metastasize [42].

The results of C5 enrichment analysis in the high immune score group suggested that the infiltration of immune cells in the TME of CRC might be related to the following biological functions: amide binding, response to wounding, endosomal part, calcium ion transmembrane transport, and endocytic vesicle (Fig 2D). The biological function of amide binding was of the highest NES in the high immune score (Fig 2C, S1 Appendix), which indicated that this gene set might regulate the immune response in patients with CRC by inducing related amide binding, that was consistent with the previous research [43].

DEGs

The DEGs of HSS vs LSS and HIS vs LIS were integrated to obtain the union of 1557 DEGs (S2 Appendix). Heat map showed the different expression levels of the top 50 genes between the stromal score groups and immune score groups (Fig 3A and 3B). The results showed that 357 genes were upregulated and 472 genes were downregulated between the immune score groups (|logFC| > 2, adjusted P < 0.05, Fig 3C); 929 genes were upregulated and 115 genes were downregulated between the stromal score groups (|logFC| > 2, adjusted P < 0.05, Fig 3D).
Network pharmacological analysis indicated the importance of each gene in SJZD treatment

Through the TCMSP database, a total of 139 active compounds that met the screening conditions were obtained. Some active ingredients of the four herbs of SJZD were shown in Table 1. Complete information on the active ingredients of SJZD can be found in S1 Table. The official human genes corresponding to the 230 target proteins were retrieved by using UniProtKB. Compound-target networks were constructed by using Cytoscape (Fig 4A). The degree value represents the degree of connection between the targets, and a high degree of connection indicates great importance. The top 12 targets are shown in detail in Table 2. In the network diagram, the square nodes are drug targets, and the red nodes are compounds of SJZD. The larger the node is, the greater the importance of the drug component or target is.

52 core target genes were obtained after the intersection of 1557 DEGs and 230 protein-coding genes (Fig 4B). These 52 genes were utilized to obtain a PPI network diagram (Fig 4C). Genes with larger nodes and deeper colors have higher degree values.

Biological pathways related to the target DEGs

The functional enrichment analysis of the 52 core target genes showed that they were mainly enriched in the signal transduction and expression regulation in TME of CRC. Among the enriched GO terms, there were 153 significantly enriched biological processes (BP), 17
significantly enriched cellular components (CC) and 25 significantly enriched molecular functions (MF) \( (P < 0.05) \). The main enriched GO terms included response to hypoxia and inflammatory response (Fig 5A), extracellular space, extracellular region and extracellular exosome (Fig 5B), and protein binding, receptor binding, enzyme binding and serine–type endopeptidase activity (Fig 5C). In addition, all pathways identified as enriched by the KEGG analysis

Fig 3. The expression profiles and differential expression analysis results of the top 50 characteristic genes between the high and low stromal and immune score groups. (A) The expression heat map for the top 50 DEGs based on immune score grouping. (B) The expression heatmap for the top 50 DEGs based on stromal score grouping. (C) Volcano maps based on differential expression analysis of immune score groups. (D) Volcano maps based on differential expression analysis of stromal score groups.

https://doi.org/10.1371/journal.pone.0264720.g003
were associated with TNF signaling pathway, transcriptional misregulation in cancer and pathways in cancer (Fig 5D).

Survival analysis and validation

Survival analysis of the 52 core target genes showed that HSPB1, COL3A1, SPP1, OLR1, IGFBP3 and TGFBI were associated with adverse prognosis of the 214 GEO CRC patients. Validation of 530 TCGA samples further confirmed that HSPB1, SPP1, IGFBP3 and TGFBI were indeed associated with poor prognosis. These 4 genes were identified as the main targets of SJZD in the CRC TME, called the core prognostic targets of SJZD for patients with CRC. The survival curves were shown in Figs 6 and 7.

Discussion

Network pharmacology analysis clarified a potential mechanism underlying the role of SJZD in the CRC TME and indicated that HSPB1, SPP1, IGFBP2 and TGFBI could be potential therapeutic targets in the CRC TME. GO and KEGG analysis of 52 core genes showed that they were mainly enriched in the response to hypoxia, the extracellular space, protein binding and the TNF signaling pathway. After a comprehensive analysis of these results, we supposed that the effect of SJZD on the microenvironment of CRC might be realized via the following three mechanisms: SJZD remodels the TME and prolongs the survival of patients with CRC by altering the expression of SPP1, TGFBI1 and IGFBP3, attenuating tumor hypoxia, decreasing the reactive oxygen species (ROS) level and enhancing the sensitivity to drugs. Hypoxia is a hallmark of the TME and plays roles in metastasis, therapy resistance and adverse clinical outcomes [44]. The prognosis of CRC is significantly related to the hypoxia response, immunity, and combined treatment response, and CRC commonly exhibits an immunosuppressive phenotype [45]. Epithelial-mesenchymal transition (EMT) is promoted by hypoxia to facilitate invasion, migration and extravasation of CRC cells [44]. SPP1 is considered to be related to

| Mol ID   | Chemical component                                                                 | OB (%) | DL  | Herb                        |
|----------|------------------------------------------------------------------------------------|--------|-----|-------------------------------|
| MOL000273| (2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-Octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-enoic acid | 30.93  | 0.81| Poria Cocos Wolf.             |
| MOL000275| Trametenolic acid                                                                   | 38.71  | 0.80|                              |
| MOL000276| 7,9(11)-Dehydropachyamic acid                                                      | 35.11  | 0.81|                              |
| MOL000279| Cerevisterol                                                                       | 37.96  | 0.77|                              |
| MOL01484 | Inermine                                                                           | 75.18  | 0.54| licorice                      |
| MOL01792 | DFV                                                                                | 32.76  | 0.18|                              |
| MOL00211 | Mairin                                                                             | 55.38  | 0.78|                              |
| MOL02879 | Diop                                                                               | 43.59  | 0.39| Panax Ginseng C. A. Mey.      |
| MOL00449 | Stigmasterol                                                                        | 43.83  | 0.76|                              |
| MOL00358 | β-Sitosterol                                                                        | 36.91  | 0.75|                              |
| MOL03648 | Inermin                                                                            | 65.83  | 0.54|                              |
| MOL00022 | 14-Acetyl-12-senecioyl-2E,8Z,10E-atractylentriol                                   | 63.37  | 0.3 | Atractylodes Macrocephala Koidz. |
| MOL00033 | (3S,8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-[(2R,5S)-5-propan-2-ylcyclopenta[a]phenanthren-3-ol | 36.23  | 0.78|                              |
| MOL00049 | 3β-Acetoxyatractylicone                                                           | 54.07  | 0.22|                              |
| MOL00072 | 8β-Ethoxyatractylenoide III                                                       | 35.95  | 0.21|                              |

https://doi.org/10.1371/journal.pone.0264720.t001
Fig 4. Network pharmacology analysis of SJZD. (A) Drug-active ingredient-target network diagram. The blue nodes are drug targets, and the red nodes are compounds of SJZD. (B) Intersection of 230 therapeutic targets and 1557 DEGs related to SJZD. (C) PPI network diagram of the 52 core genes. The larger nodes in the inner ring represented the most important hub nodes. The smaller nodes in the outer ring represent the other nodes (several nodes with degrees of 1 were deleted).

Table 2. A partial information table for the core targets.

| Targets | Degree | Targets | Degree |
|---------|--------|---------|--------|
| PTGS2   | 86.0   | PRSS1   | 57.0   |
| ESR1    | 77.0   | GSK3B   | 56.0   |
| NOS2    | 67.0   | SCN5A   | 53.0   |
| PPARG   | 67.0   | ESR2    | 53.0   |
| AR      | 67.0   | CCNA2   | 53.0   |
| HSP90AB1| 64.0   | PTGS1   | 52.0   |

https://doi.org/10.1371/journal.pone.0264720.t002
hypoxia, whereas the differential expression of *SPP1* might indicate a hypoxic response. Osteopontin, encoded by *SPP1*, promotes the carcinogenesis, disease progression and recurrence of CRC [46, 47]. ② The hypoxia-associated gene *TGFB1A* is upregulation in the extracellular space, and this upregulation is related to immune evasion and immunological rejection [48, 49]. ③ The *IGFBP3* gene is induced under hypoxic conditions; it regulates cell proliferation, senescence, apoptosis, and EMT and promotes the upregulation of a major cell surface receptor of hyaluronic acid, CD44 (CD44H). *IGFBP3* inhibits ROS cytotoxicity to promote CD44 expression in the hypoxic microenvironment [49–52].

SJZD might inhibit EMT by altering the expression of *TGFB1* to suppress the progression and influence the prognosis of CRC. The cellular EMT program is crucial for malignant progression; EMT is a coordinated process involving recombination of cell-extracellular matrix, protein binding, and regulation of drug resistance and tumor cell metastasis [53–55]. The hub gene *TGFB1* has been shown to efficiently activate EMT. When EMT is activated, the intracellular and extracellular structures and interactions are altered; these changes include the disruption of cell-cell junctions and reorganization of the extracellular matrix [56]. EMT endows cancer cells with tumor invasion and metastasis capabilities [57]. Research has supported that the EMT program, which is mediated by EMT-related transcription factors, could transform nonmetastatic primary carcinoma cells into invasive and metastatic cells [58].

SJZD affects protein binding in the CRC TME by altering the expression of *HSPB1*, *IGFBP3* and *SPP1*. CRC tumor cells have high metastatic ability due to their low adhesion properties [59]. Protein binding mediates the response to intestinal injury to fuel regeneration [60].
**HSPB1**, also called **HSP27**, is a marker of metastatic tumors that partitions damaged proteins and prevents protein aggregation [61]. Overexpression of **HSPB1** is associated with a poor prognosis in CRC [62].  

Research has shown that **IGFBP-3** cannot enter cells; thus, it interacts with surface proteins to accelerate tumor survival and invasion [63].  

**SPP1** alters the normal expression pattern of intestinal epithelial cells by binding the IRF8 protein, and the expression of **SPP1** is related to intestinal diseases such as ulcerative colitis [47, 64].

Nevertheless, there are still limitations and deficiencies in this study, such as the small sample size. We will explore the specific mechanism of these core genes in further research to provide a more accurate analysis of how the CRC TME affects prognosis.

**Conclusions**

In conclusion, our study explored core genes involved in the therapeutic mechanism of SJZD in the CRC TME. The results confirmed that the core genes **HSPB1, SPP1, IGFBP3** and **TGFB1** affected CRC development and prognosis by regulating hypoxia, protein binding and EMT in the extracellular matrix, which presents a new idea for the treatment of CRC.
Fig 7. Verification results of survival analysis (performed in 530 COAD samples from TCGA).

https://doi.org/10.1371/journal.pone.0264720.g007
Supporting information

**S1 Table. Basic information of some active components of SJZD.**

(DOCX)

**S1 Appendix. The details of the GSEA results.**

(XLSX)

**S2 Appendix. The list of the DEGs.**

(XLSX)

Author Contributions

Conceptualization: Jiaxin Du, Jingyan Zeng.

Data curation: Jiaxin Du, Quyuan Tao, Xinying Huang.

Formal analysis: Jiaxin Du, Ying Liu, Wenjia Lin.

Methodology: Quyuan Tao, Jingyan Zeng, Xin-lin Chen, Yi Wen.

Project administration: Quyuan Tao, Xin-lin Chen, Yi Wen.

Supervision: Zhanming Huang, He Jin, Yongchang Zhao, Lingyu Liu, Qian Xu, Xue Han, Lixia Chen, Xin-lin Chen, Yi Wen.

Validation: Quyuan Tao, Zhanming Huang, He Jin, Jingyan Zeng, Yongchang Zhao, Lingyu Liu, Qian Xu, Xue Han, Lixia Chen.

Visualization: Quyuan Tao, Ying Liu, Wenjia Lin, Xinying Huang, Jingyan Zeng.

Writing – original draft: Jiaxin Du, Quyuan Tao, Ying Liu, Wenjia Lin, Xinying Huang.

Writing – review & editing: Jiaxin Du, Quyuan Tao, Ying Liu, Zhanming Huang, He Jin, Jingyan Zeng, Yongchang Zhao, Lingyu Liu, Qian Xu, Xue Han, Lixia Chen, Xin-lin Chen, Yi Wen.

References

1. Sautès-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, et al. Tumor microenvironment is multifaceted. Cancer metastasis reviews. 2011; 30(1):13–25. Epub 2011/01/29. https://doi.org/10.1007/s10555-011-9279-y PMID: 21271351.

2. Pittet MJ. Behavior of immune players in the tumor microenvironment. Current opinion in oncology. 2009; 21(1):53–9. Epub 2009/01/07. https://doi.org/10.1097/CCO.0b013e32831bc38a PMID: 19125019; PubMed Central PMCID: PMC2901856.

3. Patel SG, Ahnen DJ. Colorectal Cancer in the Young. Current gastroenterology reports. 2018; 20(4):15. Epub 2018/04/05. https://doi.org/10.1007/s11894-018-0618-9 PMID: 29616330.

4. The Lancet O. Colorectal cancer: a disease of the young? The Lancet Oncology. 2017; 18(4):413. Epub 2017/04/04. https://doi.org/10.1016/s1470-2045(17)30202-4 PMID: 28368245.

5. Thanikachalam K, Khan G. Colorectal Cancer and Nutrition. Nutrients. 2019; 11(1). Epub 2019/01/17. https://doi.org/10.3390/nu11010164 PMID: 30646512; PubMed Central PMCID: PMC6357054.

6. Gu MJ, Huang QC, Bao CZ, Li YJ, Li XQ, Ye D, et al. Attributable causes of colorectal cancer in China. BMC cancer. 2018; 18(1):38. Epub 2018/01/07. https://doi.org/10.1186/s12885-017-3968-z PMID: 29304763; PubMed Central PMCID: PMC5756355.

7. Wang CY, Ding HZ, Tang X, Li ZG. Comparative analysis of immune function, hemorheological alterations and prognosis in colorectal cancer patients with different traditional Chinese medicine syndromes. Cancer biomarkers: section A of Disease markers. 2018; 21(3):701–10. Epub 2017/11/25. https://doi.org/10.3233/CBM-170805 PMID: 29171989.
Targeted effect of Sijunzi decoction on colorectal cancer

8. Smith FM, Cresswell K, Myint AS, Renihan AG. Is "watch-and-wait" after chemoradiotherapy safe in patients with rectal cancer? BMJ (Clinical research ed), 2018; 363:k4472. Epub 2018/11/15. https://doi.org/10.1136/bmj.k4472 PMID: 30425053.

9. Ransom D, Wilson K, Fournier M, Simes RJ, Gebski V, Yip D, et al. Final results of Australasian Gastro-intestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cancer by toxicity induced by fluoropyrimidines. Annals of oncology: official journal of the European Society for Medical Oncology. 2014; 25(1):117–21. Epub 2013/12/05. https://doi.org/10.1093/annonc/mdt479 PMID: 24299960.

10. Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacology & therapeutics. 2020; 206:107447. Epub 2019/11/23. https://doi.org/10.1016/j.pharmthera.2019.107447 PMID: 31756363.

11. Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Bioscience trends. 2015; 9(1):16–34. Epub 2015/03/20. https://doi.org/10.5582/bst.2015.01015 PMID: 25787906.

12. Zhang Y, Liang Y, He C. Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine. Chinese medicine. 2017; 12:20. Epub 2017/07/14. https://doi.org/10.1186/s13020-017-0140-2 PMID: 28700278; PubMed Central PMCID: PMC5506596.

13. Lee Si, Bae JA, Ko YS, Kim H, Kim KK. Geijigajaky ak decoction inhibits the motility and tumor-genesis of colorectal cancer cells. BMC complementary and alternative medicine. 2016; 16(1):288. Epub 2016/08/17. https://doi.org/10.1186/s12906-016-1261-z PMID: 27527352; PubMed Central PMCID: PMC4988256.

14. Lin X, Yi Z, Diao J, Shao M, Zhao L, Cai H, et al. ShaoYao decoction ameliorates colitis-associated colonic injury in rats by downregulating proinflammatory cytokines and promoting epithelial-mesenchymal transition. Journal of translational medicine. 2014; 12:105. Epub 2014/04/29. https://doi.org/10.1186/1475-2876-12-105 PMID: 24766737; PubMed Central PMCID: PMC4020205.

15. Wang X, Saud SM, Wang F, He S, Zhang X, Hua B, et al. Protective effect of ShaoYao decoction on colitis-associated colorectal cancer by inducing Nrf2 signaling pathway. Journal of ethnopharmacology. 2020; 252:112600. Epub 2020/01/26. https://doi.org/10.1016/j.jep.2020.112600 PMID: 31981745.

16. Wang Y, Liu P, Fang Y, Tian J, Li S, Xu J, et al. The Effect of Long-Term Traditional Chinese Medicine Treatment on Survival Time of Colorectal Cancer Based on propensity Score Matching: A Retrospective Cohort Study. Evidence-based complementary and alternative medicine: eCAM. 2020; 2020:7023420. Epub 2020/02/25. https://doi.org/10.1155/2020/7023420 PMID: 32089727; PubMed Central PMCID: PMC7013320 publication of this article.

17. Kuo YT, Chang TT, Muo CH, Wu MY, Sun MF, Yeh CC, et al. Use of Complementary Traditional Chinese Medicines by Adult Cancer Patients in Taiwan: A Nationwide Population-Based Study. Integrative cancer therapies. 2018; 17(2):351–41. Epub 2017/07/01. https://doi.org/10.1177/1534735417716302 PMID: 28665160; PubMed Central PMCID: PMC6041896.
24. Chen X, Yang K, Yang J, Li K. Meta-Analysis of Efficacy of Sijunzi Decoction Combined with Enteral Nutrition for the Treatment of Gastric Cancer. Nutrition and cancer. 2020; 72(5):723–33. Epub 2019/08/17. https://doi.org/10.1080/01635381.2019.1653470 PMID: 31418281.

25. Wu B, Xuan ZR. Progress in research on applying Sijunzi Decoction in treating digestive malignant tumor. Chinese journal of integrative medicine. 2007; 13(2):156–9. Epub 2007/07/05. https://doi.org/10.1007/s11655-007-0156-2 PMID: 17609919.

26. Jie Y, He W, Yang X, Chen W. Krüppel-like factor 4 acts as a potential therapeutic target of Sijunzi decoction for treatment of colorectal cancer. Cancer gene therapy. 2017; 24(9):361–6. Epub 2017/07/29. https://doi.org/10.1038/cgt.2017.25 PMID: 28752861.

27. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic acids research. 2013; 41(Database issue):D991–5. Epub 2012/11/30. https://doi.org/10.1093/nar/gks1193 PMID: 23193258; PubMed Central PMCID: PMC3531084.

28. Thorstensson M, Kirkeby LT, Hansen R, Lund LR, Sørensen LT, Gerds TA, et al. Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature. International journal of colorectal disease. 2012; 27(12):1579–86. Epub 2012/06/20. https://doi.org/10.1007/s00038-012-1517-4 PMID: 22710688.

29. Chen MS, Lo YH, Chen X, Williams CS, Donnelly JM, Criss ZK 2nd, et al. Growth Factor-Independent 1 Is a Tumor Suppressor Gene in Colorectal Cancer. Molecular cancer research: MCR. 2019; 17(3):697–708. Epub 2019/01/05. https://doi.org/10.1158/1541-7786.MCR-18-0666 PMID: 30606770; PubMed Central PMCID: PMC7387124.

30. Li Y, Gu J, Xu F, Zhu Q, Ge D, Lu C. Transcriptomic and functional network features of lung squamous cell carcinoma through integrative analysis of GEO and TCGA data. Scientific reports. 2018; 8(1):15834. Epub 2018/10/28. https://doi.org/10.1038/s41598-018-34160-w PMID: 30367091; PubMed Central PMCID: PMC6203807.

31. Jia D, Li S, Li D, Xue H, Yang D, Liu Y. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging. 2018; 10(4):592–605. Epub 2018/04/21. https://doi.org/10.18632/aging.101415 PMID: 29676997; PubMed Central PMCID: PMC5940130.

32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(43):15545–50. Epub 2005/10/04. https://doi.org/10.1073/pnas.0506558102 PMID: 16199517; PubMed Central PMCID: PMC1239896.

33. Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of cheminformatics. 2014; 6:13. Epub 2014/04/17. https://doi.org/10.1186/1758-2946-6-13 PMID: 24735618; PubMed Central PMCID: PMC4001360.

34. Su X, Kong L, Lei X, Hu L, Ye M, Zou H. Biological fingerprinting analysis of traditional Chinese medicines with targeting ADME/Tox property for screening of bioactive compounds by chromatographic and MS methods. Mini reviews in medicinal chemistry. 2007; 7(1):87–98. Epub 2007/02/03. https://doi.org/10.2174/138955707779317830 PMID: 17266641.

35. Chen ML, Shah V, Patnaik R, Adams W, Hussain A, Conner D, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharmaceutical research. 2001; 18(12):1645–50. Epub 2002/01/12. https://doi.org/10.1023/a:1013319408893:1013319408893. PMID: 11785688.

36. Ning K, Zhao X, Poetsch A, Chen WH, Yang J. Computational Molecular Networks and Network Pharmacology. BioMed research international. 2017; 2017:7573904. Epub 2017/12/19. https://doi.org/10.1155/2017/7573904 PMID: 29250548; PubMed Central PMCID: PMC5698785.

37. Zhang M, Yuan Y, Zhou W, Qin Y, Xu K, Men J, et al. Network pharmacology analysis of Chaihu Lizhong Tang treating non-alcoholic fatty liver disease. Computational biology and chemistry. 2020; 86:107248. Epub 2020/03/26. https://doi.org/10.1016/j.compbiolchem.2020.107248 PMID: 32208163.

38. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003; 13(11):2498–504. Epub 2003/11/05. https://doi.org/10.1101/gr.1239303 PMID: 14597658; PubMed Central PMCID: PMC403769.

39. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research. 2015; 43(7):e47. Epub 2015/01/22. https://doi.org/10.1093/nar/gkv007 PMID: 25605792; PubMed Central PMCID: PMC4402510.

40. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics: a journal of integrative biology. 2012; 16(5):284–7. Epub 2012/03/30. https://doi.org/10.1089/omi.2011.0118 PMID: 22455463; PubMed Central PMCID: PMC3339379.
41. Snel B, Lehmann G, Bork P, Huynen MA. STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic acids research. 2000; 28(18):3442–4. Epub 2000/09/13. https://doi.org/10.1093/nar/28.18.3442 PMID: 10982861; PubMed Central PMCID: PMC110752.

42. Hussain M, Adah D, Tariq M, Lu Y, Zhang J, Liu J. CXCL13/CXCR5 signaling axis in cancer. Life sciences. 2019; 227:175–86. Epub 2019/04/27. https://doi.org/10.1016/j.lfs.2019.04.053 PMID: 31026453.

43. Melonnette C, Pontarotti P, Pinault L, Mège JL, Devaux C, Raoul D. Could β-Lactam Antibiotics Block Humoral Immunity? Frontiers in immunology. 2021; 12:680146. Epub 2021/10/05. https://doi.org/10.3389/fimmu.2021.680146 PMID: 34603278; PubMed Central PMCID: PMC8480522.

44. Li H, Rokavec M, Jiang L, Horst D, Hermeking H. Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells. Gastroenterology. 2017; 153(2):505–20. Epub 2017/04/25. https://doi.org/10.1053/j.gastro.2017.04.017 PMID: 28435028.

45. Meng B, Zhu JM, Wang Y, Liu TT, Ding YB, Xiao WM, et al. Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-β1 in gastric cancer. PloS one. 2013; 8(5):e63777. Epub 2013/06/01. https://doi.org/10.1371/journal.pone.0063777 PMID: 23723999; PubMed Central PMCID: PMC3664596.

46. Lenos KJ, Miedema DM, Lodestijn SC, Nijman LE, van den Bosch T, Romero Ros X, et al. Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer. Nature cell biology. 2018; 20(10):1193–202. Epub 2018/09/05. https://doi.org/10.1038/s41556-018-0179-z PMID: 30177776; PubMed Central PMCID: PMC6163039.

47. Klement JD, Paschall AV, Redd PS, Ibrahim ML, Lu C, Yang D, et al. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. The Journal of clinical investigation. 2018; 128(12):5549–60. Epub 2018/11/06. https://doi.org/10.1172/JCI123960 PMID: 30395540; PubMed Central PMCID: PMC6264631.

48. Augustin RC, Delgoffe GM, Najjar YG. Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations. Cancers. 2020; 12(12). Epub 2020/12/23. https://doi.org/10.3390/cancers12123802 PMID: 33348579; PubMed Central PMCID: PMC7765870.

49. Craig SG, Humphries MP, Alderdice M, Bingham V, Richman SD, Loughrey MB, et al. Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British journal of cancer. 2020; 123(8):1280–8. Epub 2020/07/21. https://doi.org/10.1038/s41416-020-0985-5 PMID: 32684627; PubMed Central PMCID: PMC7555485.

50. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell. 2012; 21(3):309–22. Epub 2012/03/24. https://doi.org/10.1016/j.ccr.2012.02.022 PMID: 22439926.

51. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782–95. Epub 2013/10/22. https://doi.org/10.1016/j.immuni.2013.10.003 PMID: 24138885.

52. Koelzer VH, Dawson H, Andersson E, Karamitopoulo E, Masucci GV, Lugli A, et al. Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome. Translational research: the journal of laboratory and clinical medicine. 2015; 166(2):207–17. Epub 2015/03/24. https://doi.org/10.1016/j.trsl.2015.02.008 PMID: 25797890.

53. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704–15. Epub 2008/05/20. https://doi.org/10.1016/j.cell.2008.03.027 PMID: 18485877; PubMed Central PMCID: PMC2728032.

54. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature reviews Clinical oncology. 2017; 14(10):611–29. Epub 2017/04/12. https://doi.org/10.1038/nrclonc.2017.44 PMID: 28397828; PubMed Central PMCID: PMC5720366.

55. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670–91. Epub 2017/02/12. https://doi.org/10.1016/j.cell.2016.11.037 PMID: 28187288; PubMed Central PMCID: PMC5304846.

56. Donge A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nature reviews Molecular cell biology. 2019; 20(2):69–84. Epub 2018/11/22. https://doi.org/10.1038/s41580-018-0080-4 PMID: 3045476.

57. Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends in cell biology. 2019; 29(3):212–26. Epub 2018/12/31. https://doi.org/10.1016/j.tcb.2018.12.001 PMID: 30594349.
58. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 2012; 148(5):1015–28. Epub 2012/03/06. https://doi.org/10.1016/j.cell.2012.02.008 PMID: 22385965; PubMed Central PMCID: PMC3305806.

59. Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, et al. Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. British journal of cancer. 2012; 107(1):63–70. Epub 2012/05/26. https://doi.org/10.1038/bjc.2012.188 PMID: 22627320; PubMed Central PMCID: PMC3389402.

60. Chatterji P, Rustgi AK. RNA Binding Proteins in Intestinal Epithelial Biology and Colorectal Cancer. Trends in molecular medicine. 2018; 24(5):490–506. Epub 2018/04/09. https://doi.org/10.1016/j. mmolmed.2018.03.008 PMID: 29627433; PubMed Central PMCID: PMC5927824.

61. Freilich R, Betegon M, Tse E, Mok SA, Julien O, Agard DA, et al. Competing protein-protein interactions regulate binding of Hsp27 to its client protein tau. Nature communications. 2018; 9(1):4563. Epub 2018/11/06. https://doi.org/10.1038/s41467-018-07012-4 PMID: 30385828; PubMed Central PMCID: PMC6212398.

62. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell stress & chaperones. 2005; 10(2):86–103. Epub 2005/07/26. https://doi.org/10.1379/csc-99r.1 PMID: 16038408; PubMed Central PMCID: PMC1176476.

63. Zielinska HA, Daly CS, Alghamdi A, Bahl A, Sohail M, White P, et al. Interaction between GRP78 and IGFBP-3 Affects Tumourigenesis and Prognosis in Breast Cancer Patients. Cancers. 2020; 12(12). Epub 2020/12/24. https://doi.org/10.3390/cancers12123821 PMID: 33352865; PubMed Central PMCID: PMC77767108.

64. Masuda H, Takahashi Y, Asai S, Hemmi A, Takayama T. Osteopontin expression in ulcerative colitis is distinctly different from that in Crohn's disease and diverticulitis. Journal of gastroenterology. 2005, 40(4):409–13. Epub 2005/05/04. https://doi.org/10.1007/s00535-005-1567-2 PMID: 15888372.